Adjuvants containing natural and synthetic Toll-like receptor 4 ligands

Expert Review of Vaccines

Volumn 12, Issue 7, 2013, Pages 793-807

  Ireton, Gregory C ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

formulation; glucopyranosyl lipid A; lipopolysaccharide; monophosphoryl lipid A; pattern recognition receptors; Toll like receptor 4; Toll like receptor 4 agonist; vaccine adjuvant

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; 4' MPL; ADJUVANT; ALUMINUM SALT; ANTIALLERGIC AGENT; ANTINEOPLASTIC AGENT; E6020; GLA COMPOUND; HEPATITIS B VACCINE; I KAPPA B; INFLUENZA VACCINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; L BLP25; LIPID A; MITOGEN ACTIVATED PROTEIN KINASE P38; OM 174; ONT 10; PATTERN RECOGNITION RECEPTOR; PHOSPHORYL LIPID A; POLLINEX; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTIGEN RECOGNITION; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEISHMANIASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TH1 CELL; TH2 CELL; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; CHEMISTRY, PHARMACEUTICAL; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84880884007     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.811204     Document Type: Review

References (112)

1. Wack A, Rappuoli R. Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 17(4), 411-418 (2005
2. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr. Opin. Immunol. 24(3), 310-315 (2012
3. Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2(53), 53-74 (2010
4. Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10), e13677 (2010
5. Johnson AG, Gains S, Landy M. Studies on the O antigen of Salmonella ryphosa V. Enhancement of antibody response to protein antigens by purified lipopolysaccharide. J. Exp. Med. 103(2), 225-246 (1956
6. Kotani S, Takada H, Takahashi I et al. Immunobiological activities of synthetic lipid A analogs with low endotoxicity. Infect. Immun. 54(3), 673-682 (1986
7. Kotani S, Takada H, Tsujimoto M et al. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant. Infect. Immun. 49(1), 225-237 (1985
8. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS. Modulating the innate immune response by combinatorial engineering of endotoxin. Proc. Natl Acad. Sci. USA 110(4), 1464-1469 (2013
9. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002
10. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819-826 (2007
11. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem. J. 420(1), 1-16 (2009
12. Song DH, Lee JO. Sensing of microbial molecular patterns by Toll-like receptors. Immunol. Rev. 250(1), 216-229 (2012
13. Beutler BA. TLRs and innate immunity. Blood 113(7), 1399-1407 (2009
14. Pasare C, Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Microbes Infect. 6(15), 1382-1387 (2004
15. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997
16. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282(5396), 2085-2088 (1998
17. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973-983 (1996
18. Matsushima N, Tanaka T, Enkhbayar P et al. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate Toll-like receptors. BMC Genomics 8, 124 (2007
19. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21(4), 317-337 (2009
20. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nat. Immunol. 9(4), 361-368 (2008
21. Jin MS, Kim SE, Heo JY et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-Acylated lipopeptide. Cell 130(6), 1071-1082 (2007
22. Liu L, Botos I, Wang Y et al. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320(5874), 379-381 (2008
23. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191-1195 (2009
24. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of Toll-like receptors on B lymphocytes. Cell. Immunol. 236(1-2), 140-145 (2005
25. Gribar SC, Richardson WM, Sodhi CP, Hackam DJ. No longer an innocent bystander: Epithelial Toll-like receptor signaling in the development of mucosal inflammation. Mol. Med. 14(9-10), 645-659 (2008
26. Bulut Y, Michelsen KS, Hayrapetian L et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J. Biol. Chem. 280(22), 20961-20967 (2005
27. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7(5), 353-364 (2007
28. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61(2), 177-197 (2009
29. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006
30. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004
31. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: Regulation through compartmentalization. Nat. Rev. Immunol. 9(8), 535-542 (2009
32. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12), 1519-1526 (2002
33. Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011
34. Krummen M, Balkow S, Shen L et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J. Leukoc. Biol. 88(1), 189-199 (2010
35. Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181(3), 1849-1858 (2008
36. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005
37. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635-700 (2002
38. Galanos C, Lüderitz O, Rietschel ET et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 148(1), 1-5 (1985
39. Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J. Endotoxin Res. 12(4), 195-204 (2006
40. Nagai Y, Akashi S, Nagafuku M et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3(7), 667-672 (2002
41. Kobayashi M, Saitoh S, Tanimura N et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J. Immunol. 176(10), 6211-6218 (2006
42. Rietschel ET, Kirikae T, Schade FU et al. Bacterial endotoxin: Molecular relationships of structure to activity and function. FASEB J. 8(2), 217-225 (1994
43. Kumazawa Y, Matsuura M, Homma JY, Nakatsuru Y, Kiso M, Hasegawa A. B cell activation and adjuvant activities of chemically synthesized analogues of the nonreducing sugar moiety of lipid A. Eur. J. Immunol. 15(2), 199-201 (1985
44. Raetz CR. Biochemistry of endotoxins. Annu. Rev. Biochem. 59, 129-170 (1990
45. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7(3), 167-202 (2001
46. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3(4), 354-359 (2002
47. Kusumoto S, Fukase K, Fukase Y et al. Structural basis for endotoxic and antagonistic activities: Investigation with novel synthetic lipid A analogs. J. Endotoxin Res. 9(6), 361-366 (2003
48. Hajjar AM, Ernst RK, Fortuno ES 3rd et al. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog. 8(10), e1002963 (2012
49. Johnson DA, Keegan DS, Sowell CG et al. 3-O-Desacyl monophosphoryl lipid A derivatives: Synthesis and immunostimulant activities. J. Med. Chem. 42(22), 4640-4649 (1999
50. Stöver AG, Da Silva Correia J, Evans JT et al. Structure-Activity relationship of synthetic Toll-like receptor 4 agonists. J. Biol. Chem. 279(6), 4440-4449 (2004
51. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 284(46), 31982-31991 (2009
52. Seydel U, Schromm AB, Brade L et al. Physicochemical characterization of carboxymethyl lipid A derivatives in relation to biological activity. FEBS J. 272(2), 327-340 (2005
53. Ulmer AJ, Heine H, Feist W et al. Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partial structures. Infect. Immun. 60(8), 3309-3314 (1992
54. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007
55. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. Selective TRIF-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci. Signal. 5(211), ra13 (2012
56. Cekic C, Casella CR, Sag D et al. MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4. J. Immunol. 186(7), 3858-3865 (2011
57. Kim HM, Park BS, Kim JI et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130(5), 906-917 (2007
58. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316(5831), 1632-1634 (2007
59. Choe J, Kelker MS, Wilson IA. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309(5734), 581-585 (2005
60. Kang JY, Nan X, Jin MS et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31(6), 873-884 (2009
61. Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc. Natl Acad. Sci. USA 109(19), 7421-7426 (2012
62. Ribi E, Parker R, Strain S et al. Peptides as requirement for immunotherapy of the guinea-pig line 10 tumor with endotoxins. Cancer Immunol. Immunother. 12, 91-96 (1979
63. Myers K, Truchot A, Ward J, Hudson Y, Ulrich J. A critical determinant of lipid A endotoxic activity. In: Cellular and Molecular Aspects of Endotoxin Reactions. Nowotny A, Spitzler J, Ziegler E (Eds). Elsevier, Amsterdam, The Netherlands, 145-156 (1990
64. Ulrich J, Myers K. Monophosphoryl lipid A as an adjuvant. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell M, Newman M (Eds). Plenum Press, New York, NY, USA, 495-524 (1995
65. Casella CR, Mitchell TC. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65(20), 3231-3240 (2008
66. Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9(3), 264-272 (1993
67. Mitchell MS, Harel W, Kempf RA et al. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 8(5), 856-869 (1990
68. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge Jr. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2(2), 219-229 (2003
69. Wheeler CM, Castellsagué; X, Garland SM et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1), 100-110 (2012
70. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt-And TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009
71. Abdulla S, Salim N, Machera F et al. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. Malar. J. 12, 11 (2013
72. Agnandji ST, Lell B, Fernandes JF et al. A Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367(24), 2284-2295 (2012
73. Johnson AG. Molecular adjuvants and immunomodulators: New approaches to immunization. Clin. Microbiol. Rev. 7(3), 277-289 (1994
74. Galanos C, Lüderitz O, Freudenberg M et al. Biological activity of synthetic heptaacyl lipid A representing a component of Salmonella minnesota R595 lipid A. Eur. J. Biochem. 160(1), 55-59 (1986
75. Jiang ZH, Budzynski WA, Qiu D, Yalamati D, Koganty RR. Monophosphoryl lipid A analogues with varying 3-O-substitution: Synthesis and potent adjuvant activity. Carbohydr. Res. 342(6), 784-796 (2007
76. Jiang ZH, Bach MV, Budzynski WA, Krantz MJ, Koganty RR, Longenecker BM. Lipid A structures containing novel lipid moieties: Synthesis and adjuvant properties. Bioorg. Med. Chem. Lett. 12(16), 2193-2196 (2002
77. Martin OR, Zhou W, Wu X et al. Synthesis and immunobiological activity of an original series of acyclic lipid a mimics based on a pseudodipeptide backbone. J. Med. Chem. 49(20), 6000-6014 (2006
78. Ishizaka ST, Hawkins LD. E6020: A synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6(5), 773-784 (2007
79. Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14(11), 1499-1504 (2007
80. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188(5), 2189-2197 (2012
81. Wiley SR, Raman VS, Desbien A et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3(93), 93ra69 (2011
82. Mueller M, Lindner B, Kusumoto S, Fukase K, Schromm AB, Seydel U. Aggregates are the biologically active units of endotoxin. J. Biol. Chem. 279(25), 26307-26313 (2004
83. Anderson RC, Fox CB, Dutill TS et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B. Biointerfaces 75(1), 123-132 (2010
84. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19(1), 103-107 (1999
85. Childers NK, Miller KL, Tong G et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-Associated antigen. Infect. Immun. 68(10), 5509-5516 (2000
86. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009
87. Hui GS, Hashimoto CN. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int. Immunopharmacol. 8(7), 1012-1022 (2008
88. Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl. 3), S24-S33 (2002
89. Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6(5), 685-698 (2007
90. Alving CR, Matyas GR. Design and selection of vaccine adjuvants: Principles and practice. In: The Grand Challenge for the Future: Vaccines for Poverty-Related Diseases from Bench to Field. Kaufmann SHE, Lambert PH (Eds). Birkhauser Verlag, Basel, Switzerland, 99-118 (2005
91. Zhu D, Huang S, Gebregeorgis E et al. Development of a direct alhydrogel formulation immunoassay (DAFIA). J. Immunol. Methods 344(1), 73-78 (2009
92. Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26(24), 3036-3045 (2008
93. Tollemar J, Klingspor L, Ringdé;n O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin. Microbiol. Infect. 7(Suppl. 2), 68-79 (2001
94. Matyas GR, Wassef NM, Rao M, Alving CR. Induction and detection of antibodies to squalene. J. Immunol. Methods 245(1-2), 1-14 (2000
95. Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA 89(1), 358-362 (1992
96. Richards RL, Rao M, Wassef NM, Glenn GM, Rothwell SW, Alving CR. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66(6), 2859-2865 (1998
97. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30(13), 2256-2272 (2012
98. Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303-321 (2010
99. Baudner BC, Ronconi V, Casini D et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26(6), 1477-1485 (2009
100. Pichyangkul S, Gettayacamin M, Miller RS et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22(29-30), 3831-3840 (2004
101. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4), 492-503 (2010
102. Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956-5963 (2009
103. Windish HP, Duthie MS, Misquith A et al. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 29(44), 7842-7848 (2011
104. Bertholet S, Goto Y, Carter L et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27(50), 7036-7045 (2009
105. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75(9), 4648-4654 (2007
106. Coler RN, Skeiky YA, Bernards K et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiolspecific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70(8), 4215-4225 (2002
107. Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172(12), 7618-7628 (2004
108. Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect. 7(5-6), 922-931 (2005
109. Reed SG, Coler RN, Dalemans W et al. Defined tuberculosis vaccine, Mtb72F/ AS02A, evidence of protection in Cynomolgus monkeys. Proc. Natl Acad. Sci. USA 106(7), 2301-2306 (2009
110. Skeiky YA, Alderson MR, Ovendale PJ et al. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine 23(30), 3937-3945 (2005
111. Vé;lez ID, Gilchrist K, Martí;nez S et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28(2), 329-337 (2009
112. Carpenter S, O'Neill LA. Recent insights into the structure of Toll-like receptors and post-Translational modifications of their associated signalling proteins. Biochem. J. 422(1), 1-10 (2009